William T. Beck, PhD
OFFLINE

William T. Beck, PhD

1934
William T. Beck, PhD
Department Head
(312) 996-0888
Department of Biopharmaceutical Sciences
Distinguished Professor of Pharmacology and Molecular Genetics, University of Illinois at Chicago

Dr. William Beck has over 30 years in academic biomedical research and administration, much experience on federal advisory boards, and has held leadership positions in national organizations. He received his Ph.D. in Pharmacology from The George Washington University in 1971. He joined the faculty of St. Jude Children’s Research Hospital in Memphis, TN after two years at the University of Southern California and a Postdoctoral Fellowship at Yale Medical School.  In 1996 he moved to the University of Illinois at Chicago (UIC) as Professor and Director of the Cancer Center. In 1999, Dr. Beck became Head of the Department of Biopharmaceutical Sciences at UIC and Leader of the UIC Cancer Center’s Program in Cancer Targets, Therapeutics and Imaging.

1. Arslan AD, He X, Wang M, Rumschlag-Booms E, Rong L, Beck WTA High-Throughput Assay to Identify Small-Molecule Modulators of Alternative Pre-mRNA Splicing.  J Biomol Screen. 2013 Feb; 18(2):180-90

2. Cho S, Lu M, He X, Ee PL, Bhat U, Schneider E, Miele L, Beck WTNotch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci USA. 2011 Dec 20; 108(51):20778-83. 

3. Das SG, Srinivasan B, Hermanson DL, Bleeker NP, Doshi JM, Tang R, Beck WT, Xing C.Structure-Activity Relationship and Molecular Mechanisms of Ethyl 2-Amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and Its Analogues. J Med Chem. 2011 Aug 25; 54(16):5937-48. 

4. Natarajan K, Xie Y, Nakanishi T, Beck WT, Bauer KS, Ross DD. Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine. Biochim Biophys Acta. 2011 Jul; 1809(7):295-305. 

5. Chen CF, He X, Arslan AD, Mo YY, Reinhold WC, Pommier Y, Beck WTNovel regulation of NF-YB by miR-485-3p affects expression of DNA topoisomerase II and drug responsiveness. Mol Pharmacol. 2011 Apr; 79(4):735-41. 

6. He X, Arslan AD, Pool MD, Ho TT, Darcy KM, Coon JS, Beck WTKnockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene. 2011 Jan 20;30(3):356-65. 

7. Shen F, Bailey BJ, Chu S, Bence AK, Xue X, Erickson P, Safa AR, Beck WT, Erickson LC,Dynamic Assessment of Mitoxantrone Resistance and Modulation of Multidrug Resistance by PSC833 in Multidrug Resistant Human Cancer Cells, J Pharmacol Exp Ther. 2009 May 7.DOI 

8. Wu F, Zhu S, Ding Y, Beck WT, Mo YY, MicroRNA-mediated regulation of Ubc9 expression in cancer cells, Clin Cancer Res. 2009 Mar 1;15(5):1550-7. Epub 2009 Feb 17. DOI 

9. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther. 2008 Jan;324(1):95-102. Epub 2007 Oct 18. DOI 

10. Wu F, Chiocca S, Beck WT, Mo YY. Gam1-associated alterations of drug responsiveness through activation of apoptosis. Mol Cancer Ther. 2007;6:1823-30. DOI 

U54 Collaborators

Universidad de Puerto RicoThe University of Texas – MD Anderson Cancer CenterNational Cancer InstituteCenter for Reduce Cancer Health Disparities